These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24908564)

  • 1. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
    Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
    Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
    Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
    Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
    Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
    Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
    Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
    Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
    Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
    Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
    Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
    Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
    Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
    CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
    Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
    Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.
    Massot A; Vivanco R; Principe A; Roquer J; Rocamora R
    Neurologia; 2014 Mar; 29(2):94-101. PubMed ID: 23623701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.
    Villanueva V; Holtkamp M; Delanty N; Rodriguez-Uranga J; McMurray R; Santagueda P
    J Neurol; 2017 Nov; 264(11):2232-2248. PubMed ID: 28921040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
    Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
    Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
    Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
    Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.
    Mäkinen J; Rainesalo S; Peltola J
    Brain Behav; 2017 Mar; 7(3):e00634. PubMed ID: 28293474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.
    Peltola J; Holtkamp M; Rocamora R; Ryvlin P; Sieradzan K; Villanueva V
    Epilepsy Behav; 2015 Sep; 50():46-9. PubMed ID: 26114438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit.
    Giráldez BG; Garamendi-Ruiz I; Zurita J; García A; Querol R; Campos D; Cabeza-Alvarez C; Serrano P; López-González FJ; Molins A; Serratosa JM
    Acta Neurol Scand; 2019 Dec; 140(6):422-428. PubMed ID: 31498422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].
    Losch FP; Holtkamp M; McMurray R; Lendemans D; Kockelmann E
    Nervenarzt; 2016 Oct; 87(10):1094-1099. PubMed ID: 27550387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
    Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
    Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
    Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
    Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.